FERGUSON STRATEGIES, LLC for CELGENE CORPORATION
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
21st Century Cures draft legislation, specifically those sections relating to regulatory and reimbursement policies affecting the biotechnology industry. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 2, the "Medicare Access and CHIP Reauthorization Act. Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the implementation of the Prescription Drug User Fee program. Public Law No. 111-148, the "Patient Protection and Affordable Care Act," including policy and implementation issues. Public Law No. 110-85, the "Food and Drug Administration Amendments Act," including current policy issues relating to FDA's Risk Evaluation and Mitigation Strategy authority.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADAM HIGGINS | — |
| CHRIS JONES | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.